GlassScriptPhysician profile
Sean D Mccarthy
NPI 1962587089
$2,914.45
in general payments reported to CMS, 2019-2025
19 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.14 · 2020: $58.32 · 2021: $229 · 2022: $349 · 2023: $940 · 2024: $846 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $935.98 | 2020-2025 | Caplyta |
| Abbvie INC. | $385.37 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.26 | 2021-2025 | Trintellix |
| Lundbeck LLC | $257.10 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $233.00 | 2022-2025 | Rexulti |
| Alkermes, INC. | $164.46 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $136.04 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $89.22 | 2024-2025 | Auvelity |
| Corium, LLC | $87.72 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $85.12 | 2020-2025 | Austedo, Uzedy, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $74.98 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $73.44 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $40.53 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $18.00 | 2022 | |
| Acadia Pharmaceuticals INC | $16.97 | 2024 | Nuplazid |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $15.10 | 2025 | Contrave |
| Livanova USA, INC. | $14.14 | 2020 | |
| Shire North American Group INC | $13.14 | 2019 | |
| Allergan, INC. | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.